Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Testa Nivolumab med eller utan ipilimumab i bristfälligt reparationssystem (dMMR) återkommande endometriekarcinom

30 oktober 2026 uppdaterad av: National Cancer Institute (NCI)

En randomiserad fas II-studie av Nivolumab och Ipilimumab jämfört med Nivolumab monoterapi hos patienter med bristfälligt reparationssystem för missmatchning Återkommande endometriekarcinom

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To assess efficacy in terms of progression-free survival (PFS) for immunotherapy with dual immune checkpoint blockade (nivolumab/ipilimumab) versus (vs.) monotherapy (nivolumab) in patients with recurrent mismatch repair (MMR) deficient endometrial carcinoma with measurable or non-measurable (detectable) disease.

SECONDARY OBJECTIVES:

I. To evaluate the overall survival (OS) as estimated from time of enrollment to last follow-up or death.

II. To evaluate the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in those with measurable disease at start of treatment.

III. To evaluate progression-free survival at 6 months. IV. To evaluate the nature, frequency and degree of toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.

V. To evaluate PFS and objective response rate in patients with prior anti-PD1/PDL1 therapy and compare efficacy of dual immune checkpoint inhibition vs. anti-PD1 monotherapy.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or complete response (CR). Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.

ARM II: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.

MAINTENANCE THERAPY: Patients achieving CR on Arm I or II receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.

Additionally, all patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. All patients also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial.

Patients are followed every 3 months for 2 years, and then, every 6 months for 3 years.

Studietyp

Interventionell

Inskrivning (Beräknad)

81

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35233
        • Rekrytering
        • University of Alabama at Birmingham Cancer Center
        • Huvudutredare:
          • Michael D. Toboni
        • Kontakt:
    • Georgia
      • Athens, Georgia, Förenta staterna, 30607
        • Upphängd
        • University Cancer and Blood Center LLC
      • Augusta, Georgia, Förenta staterna, 30912
        • Rekrytering
        • Augusta University Medical Center
        • Kontakt:
        • Huvudutredare:
          • Bunja J. Rungruang
    • Idaho
      • Boise, Idaho, Förenta staterna, 83712
        • Rekrytering
        • Saint Luke's Cancer Institute - Boise
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Boise, Idaho, Förenta staterna, 83706
        • Upphängd
        • Saint Alphonsus Cancer Care Center-Boise
      • Caldwell, Idaho, Förenta staterna, 83605
        • Upphängd
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Förenta staterna, 83814
        • Rekrytering
        • Kootenai Health - Coeur d'Alene
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
      • Fruitland, Idaho, Förenta staterna, 83619
        • Rekrytering
        • Saint Luke's Cancer Institute - Fruitland
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Meridian, Idaho, Förenta staterna, 83642
        • Rekrytering
        • Saint Luke's Cancer Institute - Meridian
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Nampa, Idaho, Förenta staterna, 83687
        • Rekrytering
        • Saint Luke's Cancer Institute - Nampa
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Nampa, Idaho, Förenta staterna, 83687
        • Upphängd
        • Saint Alphonsus Cancer Care Center-Nampa
      • Post Falls, Idaho, Förenta staterna, 83854
        • Rekrytering
        • Kootenai Clinic Cancer Services - Post Falls
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
      • Sandpoint, Idaho, Förenta staterna, 83864
        • Rekrytering
        • Kootenai Clinic Cancer Services - Sandpoint
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60612
        • Upphängd
        • University of Illinois
      • Danville, Illinois, Förenta staterna, 61832
        • Rekrytering
        • Carle at The Riverfront
        • Huvudutredare:
          • Pratima Chalasani
        • Kontakt:
      • Effingham, Illinois, Förenta staterna, 62401
        • Rekrytering
        • Carle Physician Group-Effingham
        • Kontakt:
        • Huvudutredare:
          • Pratima Chalasani
      • Mattoon, Illinois, Förenta staterna, 61938
        • Rekrytering
        • Carle Physician Group-Mattoon/Charleston
        • Kontakt:
        • Huvudutredare:
          • Pratima Chalasani
      • Normal, Illinois, Förenta staterna, 61761
        • Rekrytering
        • Carle BroMenn Medical Center
        • Huvudutredare:
          • Pratima Chalasani
        • Kontakt:
      • Normal, Illinois, Förenta staterna, 61761
        • Rekrytering
        • Carle Cancer Institute Normal
        • Huvudutredare:
          • Pratima Chalasani
        • Kontakt:
      • Urbana, Illinois, Förenta staterna, 61801
        • Rekrytering
        • Carle Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Pratima Chalasani
    • Indiana
      • Carmel, Indiana, Förenta staterna, 46032
        • Upphängd
        • IU Health North Hospital
      • Crown Point, Indiana, Förenta staterna, 46307
        • Rekrytering
        • Northwest Cancer Center - Crown Point
        • Huvudutredare:
          • Pratima Chalasani
        • Kontakt:
      • Dyer, Indiana, Förenta staterna, 46311
        • Rekrytering
        • Northwest Oncology LLC
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 219-924-8178
        • Huvudutredare:
          • Pratima Chalasani
      • Hobart, Indiana, Förenta staterna, 46342
        • Rekrytering
        • Northwest Cancer Center - Hobart
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 219-947-1795
        • Huvudutredare:
          • Pratima Chalasani
      • Hobart, Indiana, Förenta staterna, 46342
        • Rekrytering
        • Saint Mary Medical Center
        • Huvudutredare:
          • Pratima Chalasani
        • Kontakt:
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Rekrytering
        • Indiana University/Melvin and Bren Simon Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Jessica E. Parker
      • Indianapolis, Indiana, Förenta staterna, 46312
        • Rekrytering
        • Saint Catherine Hospital
        • Huvudutredare:
          • Pratima Chalasani
        • Kontakt:
      • Munster, Indiana, Förenta staterna, 46321
        • Rekrytering
        • The Community Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 219-836-3349
        • Huvudutredare:
          • Pratima Chalasani
      • Munster, Indiana, Förenta staterna, 46321
        • Rekrytering
        • Women's Diagnostic Center - Munster
        • Kontakt:
        • Huvudutredare:
          • Pratima Chalasani
      • Valparaiso, Indiana, Förenta staterna, 46383
        • Rekrytering
        • Northwest Cancer Center - Valparaiso
        • Huvudutredare:
          • Pratima Chalasani
        • Kontakt:
    • Iowa
      • Iowa City, Iowa, Förenta staterna, 52242
        • Rekrytering
        • University of Iowa/Holden Comprehensive Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-237-1225
        • Huvudutredare:
          • David P. Bender
    • Kentucky
      • Louisville, Kentucky, Förenta staterna, 40202
        • Rekrytering
        • The James Graham Brown Cancer Center at University of Louisville
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 502-562-3429
        • Huvudutredare:
          • Jason A. Chesney
      • Louisville, Kentucky, Förenta staterna, 40245
        • Rekrytering
        • UofL Health Medical Center Northeast
        • Kontakt:
        • Huvudutredare:
          • Jason A. Chesney
    • Maine
      • Scarborough, Maine, Förenta staterna, 04074
        • Rekrytering
        • MaineHealth Maine Medical Center- Scarborough
        • Huvudutredare:
          • Leslie S. Bradford
        • Kontakt:
    • Michigan
      • Battle Creek, Michigan, Förenta staterna, 49017
        • Rekrytering
        • Bronson Battle Creek
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Upphängd
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Förenta staterna, 49503
        • Rekrytering
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Förenta staterna, 49007
        • Rekrytering
        • Bronson Methodist Hospital
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Förenta staterna, 49007
        • Rekrytering
        • West Michigan Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Förenta staterna, 49009
        • Rekrytering
        • Beacon Kalamazoo Cancer Center
        • Huvudutredare:
          • Kathleen Y. Butler
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 574-647-7370
      • Muskegon, Michigan, Förenta staterna, 49444
        • Upphängd
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Förenta staterna, 49120
        • Rekrytering
        • Corewell Health Lakeland Hospitals - Niles Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 616-391-1230
        • Huvudutredare:
          • Kathleen Y. Butler
      • Norton Shores, Michigan, Förenta staterna, 49444
        • Upphängd
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, Förenta staterna, 49677
        • Rekrytering
        • Corewell Health Reed City Hospital
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Förenta staterna, 49085
        • Rekrytering
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Förenta staterna, 49085
        • Rekrytering
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Traverse City, Michigan, Förenta staterna, 49684
        • Rekrytering
        • Munson Medical Center
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
      • Wyoming, Michigan, Förenta staterna, 49519
        • Rekrytering
        • University of Michigan Health - West
        • Kontakt:
        • Huvudutredare:
          • Kathleen Y. Butler
    • Minnesota
      • Coon Rapids, Minnesota, Förenta staterna, 55433
        • Rekrytering
        • Mercy Hospital
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Deer River, Minnesota, Förenta staterna, 56636
        • Rekrytering
        • Essentia Health - Deer River Clinic
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday
      • Duluth, Minnesota, Förenta staterna, 55805
        • Rekrytering
        • Essentia Health Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday
      • Duluth, Minnesota, Förenta staterna, 55805
        • Rekrytering
        • Miller-Dwan Hospital
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday
      • Edina, Minnesota, Förenta staterna, 55435
        • Rekrytering
        • Fairview Southdale Hospital
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Edina, Minnesota, Förenta staterna, 55435
        • Rekrytering
        • Minnesota Oncology - Edina
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Hibbing, Minnesota, Förenta staterna, 55746
        • Rekrytering
        • Essentia Health Hibbing Clinic
        • Huvudutredare:
          • Bret E. Friday
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 218-786-3308
      • Minneapolis, Minnesota, Förenta staterna, 55407
        • Rekrytering
        • Abbott-Northwestern Hospital
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Saint Louis Park, Minnesota, Förenta staterna, 55416
        • Rekrytering
        • Park Nicollet Clinic - Saint Louis Park
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Saint Paul, Minnesota, Förenta staterna, 55101
        • Rekrytering
        • Regions Hospital
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Saint Paul, Minnesota, Förenta staterna, 55102
        • Rekrytering
        • United Hospital
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Sandstone, Minnesota, Förenta staterna, 55072
        • Rekrytering
        • Essentia Health Sandstone
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday
      • Shakopee, Minnesota, Förenta staterna, 55379
        • Rekrytering
        • Saint Francis Regional Medical Center
        • Kontakt:
        • Huvudutredare:
          • Adrianne Mallen
      • Virginia, Minnesota, Förenta staterna, 55792
        • Rekrytering
        • Essentia Health Virginia Clinic
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday
    • Missouri
      • Columbia, Missouri, Förenta staterna, 65212
        • Rekrytering
        • MU Health - University Hospital/Ellis Fischel Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 573-882-7440
        • Huvudutredare:
          • Arwa M. Mohammad
      • St Louis, Missouri, Förenta staterna, 63110
        • Rekrytering
        • Washington University School of Medicine
        • Kontakt:
        • Huvudutredare:
          • Premal H. Thaker
    • Montana
      • Anaconda, Montana, Förenta staterna, 59711
        • Rekrytering
        • Community Hospital of Anaconda
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
      • Billings, Montana, Förenta staterna, 59101
        • Rekrytering
        • Billings Clinic Cancer Center
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
      • Billings, Montana, Förenta staterna, 59102
        • Rekrytering
        • Saint Vincent Frontier Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-648-6274
        • Huvudutredare:
          • Megan Petersen
      • Billings, Montana, Förenta staterna, 59106
        • Rekrytering
        • Intermountain Health West End Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 406-238-6685
        • Huvudutredare:
          • Megan Petersen
      • Bozeman, Montana, Förenta staterna, 59715
        • Rekrytering
        • Bozeman Health Deaconess Hospital
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
      • Great Falls, Montana, Förenta staterna, 59405
        • Rekrytering
        • Benefis Sletten Cancer Institute
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
      • Kalispell, Montana, Förenta staterna, 59901
        • Rekrytering
        • Logan Health Medical Center
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
      • Missoula, Montana, Förenta staterna, 59804
        • Rekrytering
        • Community Medical Center
        • Huvudutredare:
          • John M. Schallenkamp
        • Kontakt:
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68114
        • Rekrytering
        • Nebraska Methodist Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-354-5144
        • Huvudutredare:
          • Brent J. Tierney
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89106
        • Rekrytering
        • Women's Cancer Center of Nevada
        • Huvudutredare:
          • Nicola M. Spirtos
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 702-851-4672
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87106
        • Rekrytering
        • University of New Mexico Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Carolyn Y. Muller
    • New York
      • Buffalo, New York, Förenta staterna, 14263
        • Aktiv, inte rekryterande
        • Roswell Park Cancer Institute
      • Rochester, New York, Förenta staterna, 14642
        • Rekrytering
        • University of Rochester
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 585-275-5830
        • Huvudutredare:
          • Rachael Turner
      • Syracuse, New York, Förenta staterna, 13210
        • Rekrytering
        • State University of New York Upstate Medical University
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 315-464-5476
        • Huvudutredare:
          • Mary J. Cunningham
      • Webster, New York, Förenta staterna, 14580
    • North Carolina
      • Durham, North Carolina, Förenta staterna, 27710
        • Rekrytering
        • Duke University Medical Center
        • Huvudutredare:
          • Angeles A. Secord
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-275-3853
      • Raleigh, North Carolina, Förenta staterna, 27607
        • Rekrytering
        • Duke Women's Cancer Care Raleigh
        • Huvudutredare:
          • Angeles A. Secord
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 919-785-4878
    • North Dakota
      • Fargo, North Dakota, Förenta staterna, 58103
        • Rekrytering
        • Essentia Health Cancer Center-South University Clinic
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday
    • Ohio
      • Beachwood, Ohio, Förenta staterna, 44122
        • Rekrytering
        • UHHS-Chagrin Highlands Medical Center
        • Kontakt:
        • Huvudutredare:
          • Amy Armstrong
      • Centerville, Ohio, Förenta staterna, 45459
        • Rekrytering
        • Miami Valley Hospital South
        • Kontakt:
        • Huvudutredare:
          • Michael S. Guy
      • Chardon, Ohio, Förenta staterna, 44024
        • Rekrytering
        • Geauga Hospital
        • Kontakt:
        • Huvudutredare:
          • Amy Armstrong
      • Cincinnati, Ohio, Förenta staterna, 45220
        • Aktiv, inte rekryterande
        • Good Samaritan Hospital - Cincinnati
      • Cleveland, Ohio, Förenta staterna, 44195
        • Rekrytering
        • Cleveland Clinic Foundation
        • Kontakt:
        • Huvudutredare:
          • Peter G. Rose
      • Cleveland, Ohio, Förenta staterna, 44106
        • Rekrytering
        • Case Western Reserve University
        • Kontakt:
        • Huvudutredare:
          • Amy Armstrong
      • Cleveland, Ohio, Förenta staterna, 44111
        • Rekrytering
        • Cleveland Clinic Cancer Center/Fairview Hospital
        • Kontakt:
        • Huvudutredare:
          • Peter G. Rose
      • Columbus, Ohio, Förenta staterna, 43210
        • Rekrytering
        • Ohio State University Comprehensive Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Floor Backes
      • Mayfield Heights, Ohio, Förenta staterna, 44124
        • Rekrytering
        • Hillcrest Hospital Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Peter G. Rose
      • Mentor, Ohio, Förenta staterna, 44060
        • Rekrytering
        • UH Seidman Cancer Center at Lake Health Mentor Campus
        • Kontakt:
        • Huvudutredare:
          • Amy Armstrong
      • Parma, Ohio, Förenta staterna, 44129
        • Rekrytering
        • University Hospitals Parma Medical Center
        • Kontakt:
        • Huvudutredare:
          • Amy Armstrong
      • Westlake, Ohio, Förenta staterna, 44145
        • Rekrytering
        • UH Seidman Cancer Center at Saint John Medical Center
        • Kontakt:
        • Huvudutredare:
          • Amy Armstrong
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • Rekrytering
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Huvudutredare:
          • Christina Washington
      • Tulsa, Oklahoma, Förenta staterna, 74146
        • Aktiv, inte rekryterande
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Ontario, Oregon, Förenta staterna, 97914
        • Upphängd
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Förenta staterna, 97213
        • Rekrytering
        • Providence Portland Medical Center
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Portland, Oregon, Förenta staterna, 97225
        • Rekrytering
        • Providence Saint Vincent Medical Center
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
    • Pennsylvania
      • Beaver, Pennsylvania, Förenta staterna, 15009
        • Rekrytering
        • UPMC-Heritage Valley Health System Beaver
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Butler, Pennsylvania, Förenta staterna, 16001
        • Rekrytering
        • UPMC Hillman Cancer Center at Butler Health System
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Cranberry Township, Pennsylvania, Förenta staterna, 16066
        • Rekrytering
        • UPMC Hillman Cancer Center - Passavant - Cranberry
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Erie, Pennsylvania, Förenta staterna, 16505
        • Rekrytering
        • UPMC Hillman Cancer Center Erie
        • Huvudutredare:
          • Alexander B. Olawaiye
        • Kontakt:
      • Farrell, Pennsylvania, Förenta staterna, 16121
        • Rekrytering
        • UPMC Cancer Center at UPMC Horizon
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Greensburg, Pennsylvania, Förenta staterna, 15601
        • Rekrytering
        • UPMC Cancer Centers - Arnold Palmer Pavilion
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 724-838-1900
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Indiana, Pennsylvania, Förenta staterna, 15701
        • Rekrytering
        • IRMC Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Johnstown, Pennsylvania, Förenta staterna, 15901
        • Rekrytering
        • UPMC-Johnstown/John P. Murtha Regional Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 814-534-4724
        • Huvudutredare:
          • Alexander B. Olawaiye
      • McKeesport, Pennsylvania, Förenta staterna, 15132
        • Rekrytering
        • UPMC Cancer Center at UPMC McKeesport
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-647-8073
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Mechanicsburg, Pennsylvania, Förenta staterna, 17050
        • Rekrytering
        • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Monroeville, Pennsylvania, Förenta staterna, 15146
        • Rekrytering
        • UPMC Hillman Cancer Center - Monroeville
        • Huvudutredare:
          • Alexander B. Olawaiye
        • Kontakt:
      • Moon Township, Pennsylvania, Förenta staterna, 15108
        • Rekrytering
        • UPMC Hillman Cancer Center in Coraopolis
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Mount Pleasant, Pennsylvania, Förenta staterna, 15666
        • Rekrytering
        • UPMC Hillman Cancer Center - Part of Frick Hospital
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • N. Huntingdon, Pennsylvania, Förenta staterna, 15642
        • Rekrytering
        • Arnold Palmer Cancer Center Medical Oncology Norwin
        • Huvudutredare:
          • Alexander B. Olawaiye
        • Kontakt:
      • Natrona Heights, Pennsylvania, Förenta staterna, 15065
        • Rekrytering
        • UPMC Cancer Center-Natrona Heights
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 724-230-3030
        • Huvudutredare:
          • Alexander B. Olawaiye
      • New Castle, Pennsylvania, Förenta staterna, 16105
        • Rekrytering
        • UPMC Hillman Cancer Center - New Castle
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • Rekrytering
        • UPMC-Magee Womens Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-647-2811
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Förenta staterna, 15215
        • Rekrytering
        • UPMC-Saint Margaret
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-784-4900
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Förenta staterna, 15219
        • Rekrytering
        • UPMC-Mercy Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-533-8762
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Förenta staterna, 15237
        • Rekrytering
        • UPMC-Passavant Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-367-6454
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Förenta staterna, 15243
        • Rekrytering
        • UPMC-Saint Clair Hospital Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-502-3920
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Förenta staterna, 15232
        • Rekrytering
        • UPMC Hillman Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-647-8073
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Seneca, Pennsylvania, Förenta staterna, 16346
        • Rekrytering
        • UPMC Cancer Center at UPMC Northwest
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 814-676-7900
        • Huvudutredare:
          • Alexander B. Olawaiye
      • Washington, Pennsylvania, Förenta staterna, 15301
        • Rekrytering
        • UPMC Cancer Center-Washington
        • Kontakt:
        • Huvudutredare:
          • Alexander B. Olawaiye
      • West Mifflin, Pennsylvania, Förenta staterna, 15122
        • Rekrytering
        • UPMC West Mifflin-Cancer Center Jefferson
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 412-653-8100
        • Huvudutredare:
          • Alexander B. Olawaiye
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02905
        • Rekrytering
        • Women and Infants Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 401-274-1122
        • Huvudutredare:
          • Cara A. Mathews
    • Texas
      • Dallas, Texas, Förenta staterna, 75390
        • Rekrytering
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Kontakt:
        • Huvudutredare:
          • David S. Miller
      • Dallas, Texas, Förenta staterna, 75235
      • Fort Worth, Texas, Förenta staterna, 76104
        • Upphängd
        • UT Southwestern/Simmons Cancer Center-Fort Worth
      • Richardson, Texas, Förenta staterna, 75080
        • Rekrytering
        • UT Southwestern Clinical Center at Richardson/Plano
        • Kontakt:
        • Huvudutredare:
          • David S. Miller
    • Virginia
      • Charlottesville, Virginia, Förenta staterna, 22908
      • Richmond, Virginia, Förenta staterna, 23229
        • Rekrytering
        • Henrico Doctor's Hospital
        • Huvudutredare:
          • Andrew S. Kennedy
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 804-591-4152
      • Richmond, Virginia, Förenta staterna, 23298
        • Aktiv, inte rekryterande
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Edmonds, Washington, Förenta staterna, 98026
        • Rekrytering
        • Swedish Cancer Institute-Edmonds
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Issaquah, Washington, Förenta staterna, 98029
        • Rekrytering
        • Swedish Cancer Institute-Issaquah
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Seattle, Washington, Förenta staterna, 98122
        • Rekrytering
        • Swedish Medical Center-First Hill
        • Huvudutredare:
          • Dan S. Zuckerman
        • Kontakt:
      • Seattle, Washington, Förenta staterna, 98109
        • Aktiv, inte rekryterande
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Ashland, Wisconsin, Förenta staterna, 54806
        • Rekrytering
        • Duluth Clinic Ashland
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday
      • Ashland, Wisconsin, Förenta staterna, 54806
        • Rekrytering
        • Northwest Wisconsin Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Bret E. Friday

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Patients with measurable or non-measurable (detectable) recurrent endometrial cancer

  • Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined per RECIST 1.1 criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI

  • Non-measurable (detectable) disease in a patient is defined in this protocol per RECIST 1.1 criteria as one who does not have measurable disease but has at least one of the following conditions:

    • All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or pathological lymph nodes with >= 10 to < 15 mm short axis), are considered non-measurable disease
    • Ascites and/or pleural effusion attributed to tumor
    • Solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions

  • Patients must have endometrial cancer with deficient mismatch repair system. All patients must have institutional immunohistochemistry (IHC) and/or microsatellite instability (MSI) testing to determine mismatch repair (MMR) status. MMR deficiency is defined as lack of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6, EPCAM) by immunohistochemistry and/or presence of microsatellite instability high using the National Cancer Institute (NCI)-5plex and Promega v1.2 assays, or institutional standards (e.g. next-generation sequencing [NGS] panel)

    • Method(s) of detection of MMR deficiency will be recorded for each patient. An institutional pathology report, and additional reports if available, documenting these results must be submitted. Patients with "equivocal" results on MMR testing by immunohistochemistry may be eligible if they have documented evidence of microsatellite instability by MSI testing or by next generation sequencing assays. MMR testing by IHC may be used to resolve equivocal/indeterminate MSI results

  • Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, mucinous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)

  • Patients may have received 1-2 prior lines of systemic therapy:

    • Prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings. Patients must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition

  • Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration

  • Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to registration

  • Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, biologic agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C)

  • Age >= 18

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

  • Platelets >= 100,000/mcl

  • Absolute neutrophil count (ANC) >= 1,500/mcl

  • Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN)

  • Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =<3 x ULN may be enrolled)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN

  • Adequate oxygen saturation via pulse oximeter (CTCAE v.5.0 hypoxia < grade 2 within 28 days prior to registration)

  • Thyroid-stimulating hormone (TSH) within normal limits (TSH < ULN allowed in euthyroid patients on thyroid replacement therapy). TSH testing is only required if clinically indicated

  • Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy. At least 4 weeks must have elapsed since major surgery

  • As clinically indicated, patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better and have a corrected QT (QTc) interval < 450 msec

  • The effects of nivolumab, and ipilimumab on the developing human fetus are unknown. For this reason and because nivolumab and ipilimumab are known to be teratogenic, women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception

    • WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial

  • Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and the patient is stable off steroids for at least one month

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

  • Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible

  • Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible

Exclusion Criteria:

  • Patients with a diagnosis of endometrial serous carcinoma or carcinosarcoma

  • Patients who received prior anti-PD1/PD-L1 therapy and had grade 3-4 or recurring grade 2 immune-related toxicities that led to dose delay or discontinuation of immunotherapy due to those toxicities

  • Patients who received anti-CTLA-4 therapy or other immunotherapeutic agents

  • Patients on chronic steroid therapy except those on replacement therapy at a daily dose of 10mg or less prednisone or equivalent

  • Patients on immunosuppressive therapy, with the exception of:

    • Intra-nasal, inhaled, topical or local steroid injections
    • Premedication for hypersensitivity reaction

  • Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease

  • Patients with known immune impairment who may be unable to respond to anti-CTLA-4 antibody

  • Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Women who are pregnant or unwilling to discontinue nursing

  • Prior therapy with CTLA-4 inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, and/or ipilimumab including severe hypersensitivity reactions to any monoclonal antibody

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm I (nivolumab and ipilimumab)

Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or CR. Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.

MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.

Additionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial.
Biologisk: Ipilimumab

Given IV

Andra namn:
  • Anti-cytotoxisk T-lymfocyt-associerad antigen-4 monoklonal antikropp
  • BMS-734016
  • Ipilimumab Biosimilar CS1002
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010
Procedur: Computed Tomography

Undergo CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp
Procedur: Magnetic Resonance Imaging

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI
Biologisk: Nivolumab

Given IV

Andra namn:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Procedur: Biospecimen Collection

Undergo collection of tissue and/or blood samples

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling
Aktiv komparator: Arm II (nivolumab)

Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.

MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.

Additionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial.
Procedur: Computed Tomography

Undergo CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp
Procedur: Magnetic Resonance Imaging

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI
Biologisk: Nivolumab

Given IV

Andra namn:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Procedur: Biospecimen Collection

Undergo collection of tissue and/or blood samples

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression-free survival (PFS)
Tidsram: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years after randomization

The statistical test used for decision making is the stratified, standardized log-rank test (Z) based on PFS. For the safety lead-in analysis, the primary endpoint is the observation of at least one dose-limiting toxicity (DLT) in the first 3 cycles of treatment. Patients are classified as having a DLT in 3 cycles or receiving adequate treatment.
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years after randomization

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall survival (OS)
Tidsram: Up to 5 years after randomization

Will be assessed when the PFS data are mature. The null hypothesis will be that the hazard of death in regimen 1 is equal to the hazard of death in regimen 2. That is, Ho: HR = 1.00. The alternative will be that Ha: HR < 1.00 (regimen 1 to 2). The number of deaths is unknown.
Up to 5 years after randomization
Objective tumor response (ORR)
Tidsram: Up to 5 years after randomization

Defined as the frequency of patients who have either a partial or complete response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The number of patients with responses will be tabulated by the treatment they were randomized to. Fisher's Exact Test will be used to test the hypothesis that the probabilities of response in each arm is the same. ORR will be evaluated only in patients who had measurable disease per RECIST 1.1 before starting treatment.
Up to 5 years after randomization
Progression-free survival (PFS) at 6 months
Tidsram: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 6 months after randomization

A patient who survives at least 6 months progression-free will be considered to have had a successful outcome. Those who progress or die within 6 months are considered treatment failures, and those who survive progression-free for less than 6 months will be considered to have an unknown outcome or indeterminate. If the patient's status cannot be determined, she will be moved to the "failure" status for analysis. Like tumor response, the hypothesis of equivalent probabilities will be assessed with Fisher's Exact Test.
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 6 months after randomization
Incidence of adverse events
Tidsram: Up to 5 years after randomization

Will be assessed by Common Terminology Criteria for Adverse Events (CTCAE). Will be tabulated by frequency and severity by treatment regimen. The treatment regimens will be compared by classifying the toxicities as severe or not and tested for equivalent probabilities by Fisher's Exact Test or whether the estimated probabilities of severe toxicities diverge by more than 10%.
Up to 5 years after randomization

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

National Cancer Institute (NCI)

Samarbetspartners

NRG Oncology

Utredare

  • Huvudutredare: Haider S Mahdi, NRG Oncology

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 juni 2022

Primärt slutförande (Beräknad)

30 juli 2032

Avslutad studie (Beräknad)

30 juli 2032

Studieregistreringsdatum

Först inskickad

6 november 2021

Först inskickad som uppfyllde QC-kriterierna

6 november 2021

Första postat (Faktisk)

9 november 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 oktober 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • NCI-2021-11881
  • U10CA180868 (U.S.S. NIH-anslag/kontrakt)
  • NCI-2021-11881 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
  • NRG-GY025 (Annan identifierare: CTEP)
  • NRG-GY025 (Annan identifierare: NRG Oncology)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera